Soligenix Announces Initiation Of A Phase 1/2 Clinical Trial Of SGX201 For The Prevention Of Acute Radiation Enteritis

Links shared publicly online about this topic.

1,512
total visits

Soligenix Announces Initiation Of A Phase 1/2 Clinical Trial Of SGX201 For The Prevention Of Acute Radiation Enteritis

Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced that it has initiated a Phase 1/2 clinic

View full resource at medicalnewstoday.com

Tags: Healthcare, Clinical Trial, Biotech, Radiation

Most Recently Shared on December 22, 2009 at 12:04 pm By:

MNT Clinical Trials

Soligenix Announces Initiation Of A Phase 1/2 Clinical Trial Of SGX201 For The Prevention Of Acute Radiation Enteritis http://mnt.to/3vKR

2 years ago...

Retweet

Favorite

Soligenix Initiates Radiation Enteritis Prevention Moves | Radiology

medicexchange.com — “DOR BioPharma, Inc. announced that it has initiated a Phase 1/2 clinical trial evaluating SGX201, a time-release formulation of oral beclomethasone 17,21-dipropionate (oral BDP)” View full resource at medicexchange.com